Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data suggest that adjuvant pembrolizumab can prolong disease-free survival in patients with renal cell carcinoma across risk groups and disease stages. Data suggest that adjuvant pembrolizumab can prolong disease-free survival in patients with RCC across risk groups and disease stages.
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Volatility and Risk Cocrystal Pharma has a […]
TME PHARMA ANNOUNCES FURTHER IMPROVEMENT IN MEDIAN OVERALL SURVIVAL AT 19 MONTHS FOLLOW-UP IN GLORIA BRAIN CANCER TRIAL Median overall survival...
Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 combination with radiotherapy and bevacizumabSurvival rate in this cohort at 19 months is 10-fold greater than a reference cohort of matched patients receiving standard of care (50% vs. 5%)BERLIN--(BUSINES...